Industry Research
-
COVID Continues To Impact Outsourced Manufacturing And Supply Chain Security
4/3/2023
ISR shares results from its annual benchmarking surveys on how the COVID-19 pandemic has impacted outsourced manufacturing over the past three years as well as how drug innovators plan to reduce risk and improve supply chain security going forward.
-
Decentralized Clinical Trial Predicted Use
4/3/2023
Though not all respondents to ISR’s Decentralized Clinical Trials Market Outlook reported a smooth experience, nearly 60% came away with a positive overall impression of DCTs.
-
How Well Are CDMOs Performing On Sponsors' Most Important CDMO Selection Criteria?
3/1/2023
Focusing on the 20 common CDMO attributes that serve as both selection drivers and also performance metrics, ISR compared how well contract manufacturers are performing on the criteria that matter the most among sponsors.
-
Clinical Manufacturing Volume By Service Provider Category
2/1/2023
When it comes to outsourced clinical manufacturing, respondents allocate the largest proportion of project volume to a combination of drug substance and drug product CDMOs.
-
Phase 1 Study Complexity
1/3/2023
ISR recently ran a survey to assess dynamics in the Phase 1 clinical development space. Over 80% of respondents believe Phase 1 studies are getting more complex.
-
The Top Reasons Bioprocessing CDMOs Lose Bids
12/1/2022
Respondents continue to report that service providers primarily lose bids for bioprocessing efforts due to regulatory violations/FDA form 483 warnings, their inability to meet required timelines, and high cost.
-
Preferred Provider Agreements At Small & Emerging Sponsors
11/1/2022
While preferred provider agreements are an important piece of the provider-selection puzzle in many parts of clinical development, this is not necessarily the case among small sponsors.
-
Where Bioprocessing Outsourcers Stand On Capacity Concerns
10/3/2022
Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.
-
Outsourced Proportion Of Phase 2/3 Spend
10/3/2022
ISR recently ran a survey to assess dynamics in the Phase 2/3 clinical development space. Survey respondents reported that, on average, two-thirds of their company’s spend on Phase 2/3 studies over the past year was outsourced.
-
Volume Of Trials With Outsourced Clinical Logistics
9/1/2022
ISR’s Clinical Logistics Market Dynamics report provides details on drug developers’ use of the various types of service providers available for outsourced clinical logistics.